Journal of Vaccine Research 2024, Vol.14, No.4, 196-206 http://medscipublisher.com/index.php/jvr 206 Park J.W., Lagniton P.N., Liu Y., and Xu R.H., 2021, mRNA vaccines for COVID-19: what, why and how, International Journal of Biological Sciences, 17(6): 1446. https://doi.org/10.7150/ijbs.59233 PMid:33907508 PMCid:PMC8071766 Polack F., Thomas S., Kitchin N., Absalon J., Gurtman A., Lockhart S., Perez J., Marc G., Moreira E., Zerbini C., Bailey R., Swanson K., Roychoudhury S., Koury K., Li P., Kalina W., Cooper D., Frenck R., Hammitt L., Türeci Ö., Nell H., Schaefer A., Ünal S., Tresnan D., Mather S., Dormitzer P., Şahin U., Jansen K., and Gruber W.C., 2020, Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine, New England Journal of Medicine, 383(27): 2603-2615. https://doi.org/10.1056/NEJMoa2034577 PMid:33301246 PMCid:PMC7745181 Sharif N., Alzahrani K., Ahmed S., and Dey S.K., 2021, Efficacy, immunogenicity and safety of COVID-19 vaccines: a systematic review and meta-analysis, Frontiers in Immunology, 12: 714170. https://doi.org/10.3389/fimmu.2021.714170 PMid:34707602 PMCid:PMC8542872 Shaw R., Stuart A., Greenland M., Liu X., Van-Tam J., and Snape M.D., 2021, Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data, The Lancet, 397(10289): 2043-2046. https://doi.org/10.1016/S0140-6736(21)01115-6 PMid:33991480 Walsh E., Frenck R., Falsey A., Kitchin N., Absalon J., Gurtman A., Lockhart S., Neuzil K., Mulligan M., Bailey R., Swanson K., Li P., Koury K., Kalina W., Cooper D., Fontes-Garfias C., Shi P., Türeci Ö., Tompkins K., Lyke K., Raabe V., Dormitzer P., Jansen K., Şahin U., and Gruber W.C., 2020, Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates, New England Journal of Medicine, 383(25): 2439-2450. https://doi.org/10.1056/NEJMoa2027906 PMid:33053279 PMCid:PMC7583697 Xuan J., 2024, Innovative antiviral strategy targeting PLpro: Discovery of Jun12682 and analysis of its antipandemic effects, International Journal of Molecular Medical Science, 14(1): 56-60. https://doi.org/10.5376/ijmms.2024.14.0008 Zhu F., Guan X., Li Y., Huang J., Jiang T., Hou L., Li J., Yang B., Wang L., Wang W., Wu S., Wang Z., Wu X., Xu J., Zhang Z., Jia S., Wang B., Hu Y., Liu J., Zhang J., Qian X., Li Q., Pan H., Jiang H., Deng P., Gou J., Wang X., Wang X., and Chen W., 2020a, Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial, The Lancet, 396(10249): 479-488. https://doi.org/10.1016/S0140-6736(20)31605-6 PMid:32702299 Zhu F., Li Y., Guan X., Hou L., Wang W., Li J., Wu S., Wang B., Wang Z., Wang L., Jia S., Jiang H., Wang L., Jiang T., Hu Y., Gou J., Xu S., Xu J., Wang X., Wang W., and Chen W., 2020b, Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial, The Lancet, 395(10240): 1845-1854. https://doi.org/10.1016/S0140-6736(20)31208-3 PMid:32450106
RkJQdWJsaXNoZXIy MjQ4ODYzNQ==